From a patient perspective there IS an UNMET need for NDMM patients. The pts Dx with high risk disease may never make it see line 2 or 3 of treatment. Although the median survival may be 15 years, there is a group of patients that survive less than 2 yrs. They matter too #mmsm

Yesterday, in a ‘Historical’ Moment, FDA Committee Ruled on a Faster Way to Approve Therapies for Myeloma.

We were honored to present EVIDENCE meta-analysis, work I pioneered 15 yrs ago. Congrats also to I2TEAMM!

International Myeloma Foundation Multiple Myeloma RF #mmsm HealthTree Foundation Sylvester Comprehensive Cancer Center

Real world data on bridging therapy for CAR-T. Report by U.S. Myeloma Immunotherapy Consortium Aimaz Afrough Yi Lin Surbhi Sidana, MD Gurbakhash Kaur Larry Anderson,MD,PhD,FACP Shonali Midha, M.D. Hamza Hashmi Krina Patel Douglas W. Sborov MD MS Omar Nadeem et al.

nature.com/articles/s4140…

Check out my editorial: Clinical Trials of T-Cell Re-Directing Therapy in Plasma Cell Precursor Conditions #mmsm

➡️free access: authors.elsevier.com/a/1ivNN3QE--Z9…

Table 👇 with trials in MGUS&smoldering myeloma

I summarize reasons why such trials are problematic&can harm patients

IMF celebrates ODAC's historic decision on MRD testing as an early endpoint for accelerated myeloma drug approval. 10 yrs of IMF research led by Dr. Durie & i2TEAMM; & U of Miami Sylvester Comprehensive Cancer Center contributed to this decision. Bruno Paiva Nikhil C. Munshi, MD

ODAC votes 12-0 for MRD as a surrogate endpoint for accelerated approval in myeloma.

Kudos to the i2TEAMM led by Nikhil C. Munshi, MD Brian Durie, M.D. Jesus San Miguel for a monumental effort.

International Myeloma Foundation Yelak Biru

targetedonc.com/view/fda-odac-… Targeted Oncology

In NDMM, how does KRd compare to VRd regarding efficacy endpoints? Happy to share our new meta-analysis just published in AmericanJournalofHematology: doi.org/10.1002/ajh.27….

KRd-treated pts showed higher odds of achieving MRD negativity and CR/sCR compared to VRd-treated pts, while ORR,…

Using ePROs to prompt direct patient trial invitations resulted in greater enrollment to a symptom-intervention trial than standard of care physician-based referral. ja.ma/4cU8lin Nicholas Verdini Jun J. Mao Erin Gillespie, MD MPH Memorial Sloan Kettering Radiation Oncology

And the vote is in: 12 to 0 .. HUGE step for #mmsm and our patients!!! Leading the way in drug development!!

Interesting perspective about the future of CAR T cell therapy being given in the outpatient setting.

chi.scholasticahq.com/article/115793

34% of patients with advanced cancer and 29% of caregivers prioritize symptom management over life extension. Interventions to target prognostic awareness & reduce discordant goals of care can help develop realistic expectations. ja.ma/3xqIj64

IMO: MRD is a premature test, and using it as an endpoint surrogate in myeloma might be a setback to the field, especially since we don’t have strong evidence that it correlates with OS improvement yet!

#mmsm #myeloma #MedEd #USMIRC USMIRC News FDA Oncology #medtwitter

From Joshua Richter, MD, FACP in Blood Cancer Journal: Like a bridge over troubled water: keeping the myeloma down en route to CAR-T
rdcu.be/dEAj6
#MultipleMyeloma

NEW: results from the phase 3 ASAP trial comparing remission induction versus immediate allogeneic transplantation for patients with relapsed or poor responsive acute myeloid leukaemia did not show non-inferiority #leusm #openaccess thelancet.com/journals/lanha…

⬇️ A primer on #ArtificialIntelligence for everyone involved in #CancerResearch to add to their “must read” list!

aacrjournals.org/cancerdiscover…

Cancer Discovery AACR Elizabeth McKenna Eli Van Allen #AACR24

Linvoseltamab Elicits Deep Responses in Late-Stage R/R Multiple Myeloma onclive.com/view/linvoselt… via @onclive with Sundar Jagannath Icahn School of Medicine at Mount Sinai #MultipleMyeloma

Practical Hemostasis!

practical-haemostasis.com/index.html

If you want to learn hemostasis go this website and do a page or 2 every day (it's free). I consult this site quite frequently and eventually it sticks and makes me look smart in front of trainees.

Just once in my life I would like to muster the self-confidence to perform this at a karaoke bar

New #guideline on Vaccinations for Adults with Cancer are out in Journal of Clinical Oncology! A brief 🧵... 1/
Key Takeaway: Optimize vax status as a vital part of cancer care! Assess status early, vaccinate before treatment when possible, coordinate w/ PCPs & team members. ascopubs.org/doi/10.1200/JC…

CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma aacrjournals.org/cancerdiscover… MD Anderson Cancer Center